

Prophylactic oral probiotic on prevention of feeding intolerance in Very Low Birth Weight (VLBW) neonates: Randomized Clinical Trial

Original Article

Yadollah Zahed Pasha (MD)¹
Zahra Akbarianrad (MD)¹
Alireza Yahyaei Shahandashti (MD)¹
Mousa Ahmadpour-kacho (MD)¹
Mohsen Haghshenas Mojaveri (MD)^{*1}

1. Non-Communicable Pediatric Diseases
Research Center, Health Research
Institute, Babol University of Medical
Sciences, Babol, IR Iran.

* Correspondence Author:

Mohsen Haghshenas Mojaveri, Non-Communicable Pediatric Diseases
Research Center, No 19, Amirkola
Children's Hospital, Amirkola, Babol,
Mazandaran Province, 47317-41151, IR
Iran.

E-mail: matia.mojaveri@yahoo.com

Tel: +98 1132346963

Fax: +98 1132346963

Received: 7 Jan 2016

Revised: 3 Feb 2016

Accepted: 1 March 2016

Abstract:

Background: Feeding intolerance is prevalent in very low birth weight (VLBW) neonates and is a barrier for better and faster growth in these neonates. Some studies have supported the administration of oral probiotic to decrease feeding intolerance. The aim of this study was to evaluate the effect of probiotic on feeding intolerance in VLBW neonates.

Methods: This randomized clinical trial study was conducted on 60 VLBW neonates who were randomly divided into two equal groups. In the case group, the infants received probiotic in addition to routine therapy. Duration of hospitalization, time to reach to full enteral feeding and birth weight, the numbers of vomiting and defecation, c-reactive protein rising, daily weight gain were compared between two groups.

Results: No significant differences were observed between two groups in regard with gender, birth weight, method of delivery and gestational age. Mean of duration of hospitalization was 42.27 and 31.6 days in control and drug groups, respectively and there was significant difference (P-value=0.005). There was no significant difference between two groups in terms of reaching full enteral feeding, the numbers of vomiting and defecation, time to reach to birth weight, CRP rising and daily weight gain but these results were better in probiotic group.

Conclusions: This study showed that prophylactic administration of probiotic had significant role in reducing the duration of hospitalization of VLBW neonates and was effective in reaching full enteral feeding. It is suggested that the administration of probiotic can be helpful for feeding tolerance in VLBW neonates.

Keywords: Feeding Intolerance, Prevention, Oral Probiotic, , Very Low Birth Weight, Neonate

Citation:

Zahed Pasha Y, Akbarian rad Z, Yahyaei Shahandashti AR, et al. Prophylactic oral probiotic on prevention of feeding intolerance in VLBW neonates: Randomized Clinical Trial. Caspian J Pediatr March 2016; 2(1): 118-22.

Introduction:

Feeding intolerance is a well-known phenomenon in the neonatal intensive care unit (NICU) and is often associated with morbidity and mortality in preterm infants [1]. Feeding intolerance is the inability to digest enteral nutrition which is associated with gastric residual increase, abdominal distention with vomiting commonly seen in preterm infants and often leads to nutrition interruption [2]. Feeding intolerance occurs in 76.4% of VLBW neonates (under 1500 grams) [3]. Poor digestion associated with a delay in transmission can damage bowel as a premature host [4]. Necrotizing enterocolitis (NEC) is the most common acquired gastrointestinal disease in preterm infants [5]. There is not a single theory to explain the pathogenesis of necrotizing enterocolitis and many mechanisms have been proposed for it including the immature intestinal

digestion and abnormal regulated blood circulation, and the innate immune system and bacterial colonization [6].

These factors not only can cause feeding intolerance, but also lead to life-threatening conditions such as NEC [7]. Although the specific etiology of necrotizing enterocolitis is still under discussion, epidemiologic analysis determines strategic risk factors of immaturity, enteral nutrition, ischemia/asphyxia and intestinal bacterial colonization [8]. Diagnosis is based on clinical symptoms and ruling out other diseases [9].

Modified Bell classification includes stage I: suspected necrotizing enterocolitis with abdominal distention, bloody stools and vomiting/gastroesophageal residual stage II: proven necrotizing enterocolitis with symptoms associated with abdominal tenderness±metabolic acidosis and thrombocytopenia, stage III: advanced necrotizing enterocolitis with symptoms associated with hypotension, metabolic acidosis, thrombocytopenia/DIC, neutropenia [8]. Reaching to full enteral feeding can cause removing catheters, less sepsis, and other catheter-related complications [10].

Antenatal use of glucocorticoids with preferential feeding with fresh breast milk, serious prevention and treatment of sepsis and a cautious enteral nutrition are required strategies to prevent necrotizing enterocolitis [11]. Premature infants in the NICU have different intestinal microbial environment than healthy infants fed with breast milk. Contact with the native microbial environment is reduced but the exposure to organisms that had been colonized in the NICU increases due to antibiotics advising and delay in enteral feeding [12].

Many researchers have tried to modify the microbial environment of the preterm infants' gut for being similar to full-term breastfed babies hoping that growth and development will be improved and the nosocomial episodes of infection and necrotizing enterocolitis will be decreased [13]. Recent studies have investigated the use of probiotic for the prevention of necrotizing enterocolitis in preterm infants and convinced neonatologists to apply them routinely in the near future [14]. Several proposed mechanisms include maintenance of mucosal barrier, preventing bacterial replacement, setting to bacterial colonization, enabling the general resistance of the body and regulating intestinal inflammation [15].

Probiotic, prebiotics and symbiotic are essential to prevent this disease [16]. Recent studies have shown that the administration of probiotic supplementation improves the feeding tolerance, time to reach full

enteral nutrition, better weight gain, lower incidence of necrotizing enterocolitis and death due to necrotizing enterocolitis (NEC) stage is lower [17, 18, 19, 20, 21, 22 and 23]. Most of the studies had investigated the probiotics effect in preventing necrotizing enterocolitis on VLBW neonates (under 1500 grams), but in this study, feeding intolerance in neonates under 1500 grams, i.e. 1000 grams, was examined.

In the current study, the probiotic drops containing three strains of bacteria (made in Iran), 1-Lactobacillus Rhamnosus 2- Lactobacillus Ruteri 3- Bifidobacterium Infantis, were used while fewer strains had been used in most studies. Experimental studies on animals and humans advocated the idea that the administration of probiotic reduced feeding intolerance and NEC which led to death in preterm neonates, but the matter is still controversial. This study was designed to investigate the feeding intolerance in neonates under 1500 grams.

Methods:

This clinical trial was conducted on 60 VLBW neonates who were randomly divided into two equal sizes (control and intervention group). Neonates with gastrointestinal obstruction, congenital heart disease, major congenital abnormalities, death in the first 72 hours of life, the babies whose mothers used probiotic supplement and the formula-fed neonates were excluded from the current study.

All patients received standard treatment, were breastfed and their information were confidential and no additional tests were not imposed on the patients. In addition, the written consent was taken from all parents before the start of treatment.

In the intervention group with reaching feeding volume to 5 cc/kg/day, 3 drops as daily oral probiotic in neonates 1500- 1000 grams and two drops in a day in infants less than 1000 grams were added to mother's milk in every 12 hours until the enteral feeding was completed (160-120 cc per kilogram for body weight).

Consumed probiotic named Pedilact manufactured by Zist takhmir company (Iran), which contained 3 strains of microorganism products as follows:

Lactobacillus reuteri (4×10⁸ - colony forming unite-cfu/gtt), Lactolacillus rhamnosus (2×10⁹ cfu/gtt) and Bifidobacterium Infantis (3×10⁸ cfu/gtt) and pharmaceutical storage was according to company protocol during the study.

In the control group, routine treatment of the underlying condition was done and there was no placebo intervention. CRP, CBC, blood cultures,

sodium, potassium, glucose, calcium, ABG (Arterial blood gas) and a chest x-ray were performed for all included patients at the initiation of the admission in NICU. Weight, time to starting of feeding, daily weight gain, numbers of vomiting and stool passing of patients were recorded. When respiratory rate was reached to 60 breaths per minute and also respiratory distress was diminished, oral feeding was started and the start time was recorded.

For all neonates, intravenous route was established and 80-100 cc per kilogram of body weight fluid were calculated and used. All patients were treated with antibiotics (ampicillin-aminoglycoside) and when the blood cultures were negative, the antibiotics were discontinued. For neonates whom their feeding reached 5 cc/kg/day, probiotic drops in the intervention group was administrated daily and until the patient's feeding reached to 120 cc/kg/day, simultaneously, with the start of high-calorie milk, probiotic drops were cut in the intervention group. The increasing amount of daily milk was similar in both groups.

This study was registered in the Iranian Registry of Clinical Trial (www.irct.ir) with registration number ID: IRCT2015111925125N1. The study was approved by the local Ethics Committee of Babol University of Medical Sciences, Iran. All patients gave informed written consent. Data collection was done via observing and recording the information in the questionnaire by a trained nurse in NICU. Data were

analyzed using SPSS 21, T-test and X2 tests and Kaplan-Meier and Cox regression methods were also used in the present study and $P < 0.05$ was considered significant.

Results:

VLBW neonates were examined in two groups. There was no significant difference between gender, birth weight, mode of delivery (vaginal delivery or C-section) and gestational age (Table 1).

. This study showed that probiotics had significant impact on reducing the duration of hospitalization (P Value=0.05). Also in the intervention group, time to oral feeding and reach to birth weight (Table 2), incidence of sepsis and numbers of vomiting and stool passing were less than the control group, but the difference was not statistically significant.

No significant difference was observed between the two groups for $NEC \geq$ Stage II Bell, but two deaths occurred in the intervention group, who were less than 1000gr and none of them had positive blood cultures. Moreover, one of these two dead infants had hyperkalemia and hyponatremia and the other one had NEC with CRP rising; however, mortality in both groups had not significant difference (0.492) (Table 3). One of them was intra uterine growth retarded (IUGR) infant, too.

Table 1. Basic demographic characteristics in newborns into drug and control group*

Variables		drug (n=30)	control (n=30)	P Value
Sex	Male	16 (53.3)	13 (43.3)	0.438
	Female	14 (46.7)	17 (56.7)	
Type of delivery	Caesarean section	25 (83.3)	21 (70)	0.222
	Normal	5 (16.7)	9 (30)	
Birth weight (mean±SD)		1245±176	1223±206	0.667
Gestational age (weeks) (mean±SD)		30.24±1.57	30.4±2.65	0.775

*There was no significant difference between gender, birth weight, mode of delivery and gestational age

Table 2. Outcomes of birth weight, time to full enteral feeding and duration of hospitalization in drug and control group* (n=60)

Variables	Group	Mean (CI=95%)	Median (CI=95%)	P Value Range Test (10)
Time to birth weight (days)	drug	18 (14.01-21.99)	16.43 (14.22-18.64)	0.058
	control	19 (16.70-21.30)	18.87 (15.81-21.2)	
Time to oral feeding (days)	drug	10 (9.11-10.90)	10.43 (9.43-11.44)	0.253
	control	10 (8.94-11.06)	11.23 (9.76-12.71)	
Duration of hospitalization (days)	drug	30 (26.17-33.83)	31.16 (35.49-26.82)	0.005
	control	40 (23.90-56.10)	42.77 (35.32-50.22)	

* - Done with survival analysis by Kaplan-Meier method

- No significant difference was observed between the two groups for Time to birth weight and Time to oral feeding

- Significant impact on reducing the duration of hospitalization (P Value=0.05)

Table 3. comparing vomiting, increasing CRP*, 2≤NEC, daily stool numbers, daily weight gain and death in the drug and control groups (60 = n)**

Variables	Probiotic (n=30)	Control (n=30)	P Value
Vomit(Number/day)	11 (36.7)	14 (46.7)	0.432
Increasing CRP(mg/dl)	4 (13.3)	3 (10.1)	0.500
NEC Bell stage≥2	1 (3.3)	1 (3.3)	1.000
Bowel movements per day (SD±mean)	2.67±0.39	2.68±0.47	0.484
Daily weight gain(gr) (SD ± mean)	15.92±5.32	13.8±5.53	0.135
Death	2 (6.7)	0 (0)	0.492

* CRP(C-Reactive protein)

** No significant difference was observed between the two groups for all data

Discussion:

This clinical trial evaluated the effect of probiotics in the prevention of feeding intolerance in VLBW neonates and showed that prophylactic probiotic was effective in reducing the duration of hospital stay and although it had better outcomes in other cases such as vomiting and increased CRP and daily stool numbers and daily weight gain and reaching to full enteral feeding and time to achieve weight birth in the probiotic group compared to control group, this difference was not significant. Though the death was not significant in both groups, the administration of probiotic would be done cautiously and carefully due to the mortality of two neonates under 1000 gr.

In a study performed by Cheng Huan et al., the incidence of feeding intolerance, time to full enteral feeding and serum bilirubin level was lower and weight gain was faster in the treatment group. Side effects were not observed in the intervention group so their results were nearly identical to the present study. [17].

Al-Hosni et al. showed that although the nutrition with probiotic improved growth of neonates less than 1000 grams, the improvement was not observed in some infants with developmental delay in 34 weeks. Moreover, no side effects of probiotic were reported [18]. The results of their study were in consistent with those of the current study because of different kinds of probiotic, probiotic prescription time and neonates less than 1000 grams. However, in their study, the incidence of NEC and death was similar to the present study.

Fernandez et al. evaluated the probiotic effect on the prevention of necrotizing enterocolitis in neonates under 1500 grams and they indicated that NEC reduced in the study group (8% compared with 16% in the control group) [20] so their study was consistent with the present study.

In a study performed by Yang et al, NEC≥ stage II and death were significantly lower in the probiotic group, but the risk of sepsis was not different between

two groups and there was no difference between two groups in terms of weight gain and reach to enteral feeding [16].

Their study showed that at least the probiotic did not increase sepsis and mortality while in the current study, the mortality was observed because the neonates of this study were under 1000. The similarity of these two studies is that the probiotic can shorten the duration of the hospitalization.

The results of the present study indicated that the administration of prophylactic probiotic was effective in reducing the duration of hospitalization of VLBW neonates and was effective in other cases such as vomiting and increased CRP and daily stool numbers and daily weight gain and reaching to full enteral feeding and time to achieve weight birth, while the difference was not significant. Therefore, it cannot be concluded that the probiotic does not induce side effects in VLBW neonates and it must be cautiously prescribed for this group of neonates especially for ones under 1000 gr.

Finally, it is suggested that further studies should be done with larger sample size and changing the consumed dose and the duration of administration.

Acknowledgment:

We are grateful to the Clinical Research Development Committee of Amirkola Children's Hospital and Mrs Faeze Aghajanzpour, the Research Council and Non communicable Pediatric Diseases Research Center, Health Research Center Babol University of Medical Sciences for their support and cooperation with study.

Funding: This study was supported by a research grant and neonatal Fellow thesis of Dr Alireza Yahyaei Shahandashti from the Non-Communicable Pediatric Diseases Research Center of Babol University of Medical Sciences (Grant Number: 9440942).

Conflict of interest: There was no conflict of interest.

References:

1. Moore TA, Wilson ME. Feeding intolerance: a concept analysis. *Advances in Neonatal Care* 2011; 11(3): 149-54.
2. Fanaro S. Feeding intolerance in the preterm infant. *Early Human Development*, 4th International Conference on: "Nutrition and Care of Preterm Infant: Current Issues" 2013; 89, Sup 2: S13-20.
3. Tang Z, Zhou Y, Li M. Clinical features of feeding intolerance in preterm infants. *Chin J Contemporary Pediatrics* 2011; 13(8): 627-30.
4. Lin PW, Nasr TR, Stoll BJ, editors. *Necrotizing enterocolitis: recent scientific advances in pathophysiology and prevention. Seminars in perinatology*; 2008: Elsevier.
5. Wang Q, Dong J, Zhu Y. Probiotic supplement reduces risk of necrotizing enterocolitis and mortality in preterm very low-birth-weight infants: an updated meta-analysis of 20 randomized, controlled trials. *J pediatric surgery* 2012; 47(1): 241-8.
6. Mihatsch WA, Braegger CP, Decsi T, et al. Critical systematic review of the level of evidence for routine use of probiotics for reduction of mortality and prevention of necrotizing enterocolitis and sepsis in preterm infants. *Clinical nutrition* 2012; 31(1): 6-15.
7. Carter BM. Feeding intolerance in preterm infants and standard of care guidelines for nursing assessments. *Newborn and Infant Nursing Reviews* 2012; 12(4): 187-201.
8. Martin RJ, Fanaroff AA, Walsh MC. *Fanaroff and Martin's Neonatal-Perinatal Medicine: Diseases of the Fetus and Infant: Elsevier Health Sciences*; 10th edition. 2015: 1423-32.
9. Jacobs SE, Tobin JM, Opie GF, et al. Probiotic effects on late-onset sepsis in very preterm infants: a randomized controlled trial. *Pediatrics* 2013; 132(6): 1055-62.
10. Dutta S, Singh B, Chessell L, et al. Guidelines for feeding very low birth weight infants. *Nutrients* 2015; 7(1): 423-42.
11. Deshpande GC, Rao SC, Keil AD, Patole SK. Evidence-based guidelines for use of probiotics in preterm neonates. *BMC medicine* 2011; 9(1): 1-3.
12. Deshpande G, Rao S, Patole S. Probiotic for prevention of necrotizing enterocolitis in preterm neonates with very low birth weight: a systematic review of randomized controlled trials. *Lancet* 2007; 369(9573): 1614-20.
13. Underwood MA, Salzman NH, Bennett SH, et al. A randomized placebo-controlled comparison of two prebiotic/probiotic combinations in preterm infants: impact on weight gain, intestinal microbiota, and fecal short chain fatty acids. *J Pediatric Gastroenterol Nutr* 2009; 48(2): 216.
14. Neu J. Gastrointestinal development and meeting the nutritional needs of premature infants. *American J Clin Nutri* 2007; 85(2): 629S-34S.
15. Bin-Nun A, Bromiker R, Wilschanski M, et al. Oral probiotics prevent necrotizing enterocolitis in very low birth weight neonates. *J Pediatr* 2005; 147(2): 192-6.
16. Yang Y, Guo Y, Kan Q, et al. A meta-analysis of probiotics for preventing necrotizing enterocolitis in preterm neonates. *Brazilian J Med Biolog Res* 2014; 47(9): 804-10.
17. Huan C. Effects of Probiotics on Nutritional Support for Very Low Birth Weight Infants. *Med J Qilu* 2010; 5: 025.
18. Al-Hosni M, Duenas M, Hawk M, et al. Probiotics-supplemented feeding in extremely low-birth-weight infants. *J Perinatol* 2012; 32(4): 253-9.
19. Lin HC, Su BH, Chen AC, et al. Oral probiotics reduce the incidence and severity of necrotizing enterocolitis in very low birth weight infants. *Pediatrics* 2005; 115(1): 1-4.
20. Fernandez-Carrocera LA, Solis-Herrera A, Cabanillas-Ayón M, et al. Double-blind, randomised clinical assay to evaluate the efficacy of probiotics in preterm newborns weighing less than 1500 g in the prevention of necrotising enterocolitis. *Arch Disease Childhood-Fetal and Neonatal Edition*. 2013; 98(1): F5-F9.
21. Hartel C, Pagel J, Rupp J, et al. Prophylactic use of *Lactobacillus acidophilus/Bifidobacterium infantis* probiotics and outcome in very low birth weight infants. *J pediatr* 2014; 165(2): 285-9. e1.
22. Bauer CR, Morrison JC, Poole WK, et al. A decreased incidence of necrotizing enterocolitis after prenatal glucocorticoid therapy. *Pediatr* 1984; 73(5): 682-8.
23. Bernardo WM, Aires FT, Carneiro RM, et al. Effectiveness of probiotics in the prophylaxis of necrotizing enterocolitis in preterm neonates: a systematic review and meta-analysis. *J Pediatr* 2013; 89(1): 18-24.